Harrow entered into an agreement to acquire Melt Pharmaceuticals and plans to submit a new drug application for MELT-300, ...
Harrow, Inc. (NASDAQ: HROW), a U.S.-based provider of ophthalmic disease management solutions, announced on Friday that it ...
Harrow plans to submit a New Drug Application (“NDA”) to the FDA in 2027, with a potential U.S. commercial launch in 2028.
Asianet Newsable on MSN
Harrow To Acquire Sedation Solutions Developer Melt Pharmaceuticals – More Details Inside
The acquisition will include Melt’s lead investigational therapy, MELT-300, designed to provide rapid, predictable sedation ...
Harrow (NASDAQ:HROW) to acquire Melt Pharmaceuticals, a clinical-stage pharmaceutical company pioneering non-opioid, non-IV therapies for sedation for medical procedures in the hospital, outpatient, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback